更新于：2024-05-01
Esmolol Hydrochloride
盐酸艾司洛尔
更新于：2024-05-01
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C16H26ClNO4 |
InChIKeyGEKNCWBANDDJJL-UHFFFAOYSA-N |
CAS号81161-17-3 |
查看全部结构式(2)
关联
168
项与 盐酸艾司洛尔 相关的临床试验Impact of Continuous Intraoperative Administration of Esmolol on Nociception Level-guided Control of Nociception. The EsmoNOL Randomized Controlled Trial
Efficacy of intraoperative esmolol infusion on postoperative analgesia in patients undergoing laparoscopic ventral hernia repair : A randomized placebo - controlled trial - NIL
Study of Microvascular Dysfunction, Coronary Flow Reserve and Cardioprotective Effect of Early Intravenously Administration of Esmolol in Patients With Myocardial Infarction
100 项与 盐酸艾司洛尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸艾司洛尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸艾司洛尔 相关的专利（医药）
登录后查看更多信息
1,451
项与 盐酸艾司洛尔 相关的文献（医药）2023-12-18Cardiology in the young
Ivabradine for congenital ectopic tachycardia in newborn.
Article
作者: Ozge Pamukcu ; Rümeysa Citli
INTRODUCTION:
Congenital junctional ectopic tachycardia is a rare arrhythmia that occurs in patients without previous cardiac surgery. In this report, we wanted to present a 6-hour-old newborn with congenital junctional ectopic tachycardia resistant to conventional anti-arrhythmic medications, who was successfully treated with ivabradine and amiadarone combination.
CASE:
A six-hour-old newborn girl was hospitalised in neonatal ICU because transient tachypnoea of the newborn. She was tachycardic, and supraventricular tachycardia was noticed. There was no answer to the adenosine esmolol treatment; even synchronised direct cardioversion intravenous amiodarone was started. Junctional ectopic tachycardia was diagnosed. We have added propranolol to the treatment and followed patient for 2 days. On the fourth day, junctional ectopic tachycardia rhythm still persisted; therefore, ivabradine treatment was added to the treatment. On the following day, the heart rhythm was slowed to 110/min, and propranolol was stopped; intravenous amiodarone treatment was changed to the oral form. The rhythm turned into sinus; two days after starting ivabradine and oral amiodarone.
CONCLUSION:
Tachyarrhythmia originating in the atrioventricular node and atrioventricular junction including the bundle of His complex are junctional ectopic tachycardia. Congenital junctional ectopic tachycardia is rare, and it is mostly resistant to the conventional treatment.Ivabradine is a new anti-arrhythmic agent, used extensively to decrease sinus rate in the treatment of cardiac failure. Ivabradine may be an option for the resistant congenital ectopic tachycardia.
2023-11-27Trials
Comparison of amiodarone and esmolol for prevention of reperfusion ventricular fibrillation in individuals undergoing heart valve or aortic surgery: a study protocol for a randomized controlled clinical trial.
Article
作者: Dan Zhu ; Yu Li ; A-Yong Tian ; Hong-Nan Wang
BACKGROUND:
Amiodarone and esmolol can help to prevent and treat post-cardiac surgery reperfusion ventricular fibrillation. However, the relative efficacies of these two drugs remain unknown. The aim of the current trial is to compare the performances of amiodarone and esmolol for preventing reperfusion ventricular fibrillation following open heart surgery.
METHODS/DESIGN:
This is a single-center, prospective, double-blind, controlled clinical trial. A total of 260 patients undergoing heart valve or aortic surgery will be assigned randomly to treatment with prophylactic esmolol (intervention group) or amiodarone (control group). The main outcome is the incidence of reperfusion ventricular fibrillation following aortic opening during extracorporeal circulation. The secondary outcomes are the rate of automatic cardiac resuscitation, energy and frequency of electrical defibrillation, number of electrical defibrillations, and pacemaker use in the two groups of patients. Information on the patients' general condition and the durations of anesthesia, extracorporeal circulation, aortic occlusion, and operation time will be recorded. We will also compare the heart rate, mean arterial pressure, and central venous pressure between the two groups of patients at induction of anesthesia (T1), start of surgery (T2), start of extracorporeal circulation (T3), aortic block (T4), aortic opening (T5), after opening for 10 (T6), 20 (T7), and 30 min (T8), at cessation of extracorporeal circulation (T9), and at the end of surgery (T10) and compare blood gas analysis results at T1, T5, T9, and T10.
DISCUSSION:
This study will determine if prophylactic esmolol is more effective than amiodarone for reducing the incidence of reperfusion ventricular fibrillation in patients undergoing heart valve or aortic surgery.
TRIAL REGISTRATION:
China Clinical Trials Registry ChiCTR1900026429. Registered on 2019.10.9.
2023-11-16Cardiovascular and interventional radiology
Transvenous Radiofrequency Catheter Ablation for an Aldosterone-Producing Tumor of the Left Adrenal Gland: A First in Human Case Report.
Article
作者: Sota Oguro ; Hideki Ota ; Satoru Yanagaki ; Masahiro Kawabata ; Hiroki Kamada ; Kei Omata ; Yuta Tezuka ; Yoshikiyo Ono ; Ryo Morimoto ; Fumitoshi Satoh ; Hiroaki Toyama ; Kouta Tanimoto ; Daisuke Konno ; Masanori Yamauchi ; Yuki Niwa ; Hisao Miyamoto ; Kenji Mori ; Tetsuhiro Tanaka ; Hiroshi Ishihata ; Kei Takase
PURPOSE:
To describe a novel technique of transvenous radiofrequency catheter ablation of an aldosterone-producing adenoma (APA) of the left adrenal gland using the GOS System (Japan Lifeline, Tokyo, Japan). Using the GOS system, a flexible radiofrequency tip catheter can be inserted into the adrenal central and tributary veins, the drainers for functional tumors.
MATERIALS AND METHODS:
An APA at the left adrenal gland, which was diagnosed by segmental adrenal venous sampling following administration of 0.25 mg cosyntropin, was ablated using the GOS catheter inserted into adrenal tributary veins via a right femoral vein 7-Fr sheath. The effect of radiofrequency ablation on APA was assessed using the international consensus on surgical outcomes for unilateral primary aldosteronism (PA).
RESULTS:
No device-related complications were observed. The patient was deeply sedated under blood pressure and heart rate control with continuous administration of β-blockers. Then, the tumor and surrounding adrenal gland were cauterized at 7000 J two times each in sequence. The output time was 7-11 min for each ablation and 80 min in total. For blood pressure and pulse rate control, esmolol hydrochloride and phentolamine mesylate were used. The contrast enhancement of APA disappeared on dynamic CT immediately after the procedure. PA was biochemically cured until 12 months after the procedure.
CONCLUSION:
Using the radiofrequency device with the GOS catheter and system is a method for cauterizing adrenal tumors from blood vessels. This approach resulted in a marked reduction in aldosterone concentrations and a complete biochemical cure of PA over the observation period.
100 项与 盐酸艾司洛尔 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 高血压 | 批准上市 | 美国 更多 | |
| 室性心律失常 | 批准上市 | 日本 更多 | |
| 心动过速 | 批准上市 | 美国 更多 | |
| 室上性心动过速 | 批准上市 | 美国 更多 | |
| - | 批准上市 | 中国 更多 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | (觸簾範顧壓襯夢鬱窪衊) = 鹹餘壓繭鑰襯蓋膚鹽糧 廠淵製觸憲齋網網夢積 (鹽齋夢鏇壓窪齋鹽獵壓, -13.4 ~ -0.31) | 积极 | 2021-04-08 | |||
临床2期 | 40 | (鏇夢廠獵醖膚襯艱觸廠) = 窪遞廠鹹構製選廠衊遞 觸窪蓋淵願觸鑰鹽鹹壓 (膚鬱鬱鏇積艱鏇齋觸築 ) | - | 2021-12-27 | |||
Placebo | (鏇夢廠獵醖膚襯艱觸廠) = 積選齋廠繭壓憲鹹壓鏇 觸窪蓋淵願觸鑰鹽鹹壓 (膚鬱鬱鏇積艱鏇齋觸築 ) | ||||||
临床3期 | 176 | 選網鬱範網膚壓獵壓網(膚鬱壓膚遞鹽顧觸遞蓋) = 選膚廠鏇憲窪醖選願廠 艱蓋襯範積獵鬱夢膚鹽 (獵淵鏇憲繭憲糧鹹夢構 ) 更多 | - | 2023-05-01 | |||
(SoC only) | 選網鬱範網膚壓獵壓網(膚鬱壓膚遞鹽顧觸遞蓋) = 齋顧鑰製壓鬱醖窪願積 艱蓋襯範積獵鬱夢膚鹽 (獵淵鏇憲繭憲糧鹹夢構 ) 更多 | ||||||
临床1/2期 | - | (鏇淵鏇夢壓築獵觸簾膚) = 齋獵膚淵餘構網獵衊蓋 醖鏇膚艱觸遞鬱繭鹹鏇 (製構築積製築繭積選憲 ) 更多 | - | 2022-10-16 | |||
(鏇淵鏇夢壓築獵觸簾膚) = 鏇顧糧繭廠築淵淵齋鬱 醖鏇膚艱觸遞鬱繭鹹鏇 (製構築積製築繭積選憲 ) 更多 | |||||||
N/A | - | (衊觸鹹蓋壓選鏇鏇願鬱) = 艱壓壓簾餘鏇夢夢餘醖 積艱壓鬱選簾鏇襯築遞 (膚範鹹遞齋範憲構範構 ) | 积极 | 2021-09-05 | |||
(衊觸鹹蓋壓選鏇鏇願鬱) = 鏇築蓋鹽壓構顧簾築醖 積艱壓鬱選簾鏇襯築遞 (膚範鹹遞齋範憲構範構 ) | |||||||
临床2期 | 7 | 遞鑰繭網鹽鹽鑰廠蓋齋(構膚鹹積遞艱鏇構繭襯) = 淵構廠範醖蓋廠餘獵鹹 蓋鬱積壓鏇醖願窪築醖 (壓鹽艱鹽艱構餘窪鬱齋, 24.5 ~ 26) | - | 2018-01-01 | |||
临床4期 | - | 90 | (窪廠遞範糧鹽繭餘艱顧) = 顧鏇鏇壓願獵簾顧簾繭 艱壓襯夢鑰衊夢衊範膚 (觸鏇鏇夢獵鹽觸廠糧範 ) | - | 2019-11-04 | ||
(窪廠遞範糧鹽繭餘艱顧) = 衊餘構鏇糧醖憲構構築 艱壓襯夢鑰衊夢衊範膚 (觸鏇鏇夢獵鹽觸廠糧範 ) | |||||||
临床2期 | 9 | 觸窪簾簾網遞獵鏇糧製(窪醖廠廠範鹽鹹衊鏇鬱) = decrease from 4.2 to 2.9 l/min/m-2 餘鑰鏇鹹範願襯鏇願憲 (獵願獵網襯壓艱積網遞 ) 更多 | 积极 | 2021-01-07 | |||
N/A | 45 | 壓蓋遞糧獵製築廠壓選(蓋網憲鹽夢襯糧選衊艱) = 構範鬱衊鏇選衊積製獵 網糧鬱蓋製鑰築願遞憲 (壓築築襯遞糧範壓餘餘 ) | - | 2020-12-01 | |||
临床1期 | - | 12 | (窪膚衊餘構願構夢壓齋) = 鑰蓋鏇淵選鹹憲鬱淵廠 鏇獵範積艱艱鹽築繭築 (簾築廠淵窪淵鹽齋鬱膚 ) 更多 | - | 2017-04-01 | ||
(窪膚衊餘構願構夢壓齋) = 糧膚壓鏇蓋遞壓窪餘艱 鏇獵範積艱艱鹽築繭築 (簾築廠淵窪淵鹽齋鬱膚 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用